Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00346333 · ClinicalTrials.gov registry record · Phase 3

Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

A Phase 3 study, sponsored by National Eye Institute (NEI).

Completed
Registry status
Phase 3
Development phase
240
Enrollment target

NCT00346333: Completed Phase 3 study, sponsored by National Eye Institute (NEI).

NCT00346333 is a Phase 3 study that has completed, run by National Eye Institute (NEI). The registered enrollment target is 240 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00346333, a Phase 3 study, has completed, sponsored by National Eye Institute (NEI).

COMPLETED
Registry status
Phase 3
Development phase
240 participants
Enrollment target

Study Summary

The purpose of this trial is to determine whether lutein in addition to vitamin A will slow the course of retinitis pigmentosa.

Primary Outcome

Sum of visual field sensitivity readings in decibel(dB) to a size V target out to the 30 degree meridian in each direction of the visual field. The value presented represents annual change in dB over 4 years.

Interventions

  • DRUG Lutein
  • DIETARY_SUPPLEMENT Cornstarch control

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2003-07
Est. Completion 2008-12
Phase Phase 3
National Eye Institute (NEI)

221 total trials

What the finished NCT00346333 record still lists

NCT00346333 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).

The record links to 0 conditions, and to 2 interventions - of which Lutein is the first listed.

NCT00346333 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00346333 about?

NCT00346333 is a clinical study titled "Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A". The purpose of this trial is to determine whether lutein in addition to vitamin A will slow the course of retinitis pigmentosa.

What is the current status of trial NCT00346333?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2003-07. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00346333?

The interventions under investigation include: Lutein (DRUG), Cornstarch control (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00346333?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00346333's enrollment target sits among peer trials

240 1273rd of 2000 higher than 710 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00346333, the US trial registry maintained by the National Library of Medicine. NCT00346333 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.